Table 6.

Clinical characteristics, follow-up, and outcomes of all EXT1/EXT2-positive and EXT1/EXT2-negative LMN with proliferative features (class 5 with class 3/4 LN)

VariableEXT1/EXT2-Positive LMN, n=16/64 (25.0%)EXT1/EXT2-Negative LMN, n=31/96 (32.3%)P Valuea
Age at presentation, median (IQR), yr32 (25–43)33 (28–47)0.39
Female, n (%)15 (93.8)22 (71.0)0.07
SCr at presentation, median (IQR), mg/dl1.0 (0.8–2.0), n=151.20 (0.8–2.3), n=310.35
Proteinuria at presentation, median (IQR), g/24 h6.6 (1.5–7.9), n=133.7 (1.7–6.5), n=250.48
Proteinuria at presentation ≥3.5/d, n (%)9 (69.2), n=1315 (60), n=250.58
Hematuria, n (%)4 (25.0)13 (41.9)0.25
Other autoimmune diseases, n (%)5 (31.3)7 (22.6)0.52
Sclerosed glomeruli, median (IQR), %4.6 (0.0–12.5)20.0 (3.22–27.8)0.01
IFTA, median (IQR), %0.0 (0.0–8.75)10.0 (5.0–20.0)0.003
SCr at end of follow-up, median (IQR), mg/dl0.90 (0.8–1.5), n=131.30 (0.70–1.9), n=200.32
Proteinuria at end of follow-up, median (IQR), g/24 h0.60 (0.20–1.25), n=101.5 (0.30–3.40), n=150.12
Proteinuria at end of follow-up ≥3.5/d, n (%)0 (0.0), n=103 (20.0), n=150.13
ESKD, n (%)0 (0.0)7 (22.6)0.04
Death, n (%)0 (0.0)6 (19.4)0.06
Time of follow-up, median (IQR), mo48.6 (43.0–76.3)43.4 (27.1–77.9)0.27
  • a P<0.05 is considered significant.